Preclinical immunogenicity and safety of the cGMP-grade placental malaria vaccine PRIMVAC

BACKGROUND: VAR2CSA is the lead antigen for developing a vaccine that would protect pregnant women against placental malaria. A multi-system feasibility study has identified E. coli as a suitable bacterial expression platform allowing the production of recombinant VAR2CSA-DBL1x-2x (PRIMVAC) to envis...

Descripción completa

Detalles Bibliográficos
Autores principales: Chêne, Arnaud, Gangnard, Stéphane, Guadall, Anna, Ginisty, Hervé, Leroy, Odile, Havelange, Nicolas, Viebig, Nicola K., Gamain, Benoît
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491931/
https://www.ncbi.nlm.nih.gov/pubmed/30885725
http://dx.doi.org/10.1016/j.ebiom.2019.03.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491931/
https://www.ncbi.nlm.nih.gov/pubmed/30885725
http://dx.doi.org/10.1016/j.ebiom.2019.03.010

Ejemplares similares